TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

• Published in: Antiviral research Vol. 85; no. 3; pp. 551 - 555
• Main Authors: Haga, Shiori, Nagata, Noriyo, Okamura, Tadashi, Yamamoto, Norio, Sata, Tetsutaro, Yamamoto, Naoki, Sasazuki, Takehiko, Ishizaka, Yukihito
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.03.2010; Elsevier
• Subjects: ACE2; ADAM Proteins - antagonists & inhibitors; ADAM Proteins - biosynthesis; ADAM17 Protein; Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - pharmacology; Biological and medical sciences; Cell Line; Enzyme Inhibitors - pharmacology; Humans; Hydroxamic Acids - pharmacology; Lung - pathology; Lung - virology; Medical sciences; Membrane Glycoproteins - physiology; Mice; Mice, Inbred C57BL; Peptidyl-Dipeptidase A - metabolism; Pharmacology. Drug treatments; Receptors, Virus - metabolism; SARS coronavirus; SARS Virus - pathogenicity; SARS-CoV; Shedding; Short Communication; Spike Glycoprotein, Coronavirus; TACE; Viral Envelope Proteins - physiology; Virus Internalization; TACE; ACE2; Shedding; SARS-CoV; Lung disease; Respiratory disease; Severe acute respiratory syndrome; In vitro; Protein; Infection; Virus; In vivo; ADAM17; Coronavirus; Severe acute respiratory syndrome virus; Viral disease; Dissemination; Antiviral; Antagonist; Coronaviridae; Nidovirales; Virus penetration

Because outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) might reemerge, identifying antiviral compounds is of key importance. Previously, we showed that the cellular factor TNF-α converting enzyme (TACE), activated by the spike protein of SARS-CoV (SARS-S protein), was positive...